On October 30, 2018 Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, reported that the Company will present data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, in advanced solid tumor patients in an oral plenary session at the 30th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Molecular Targets and Cancer Therapeutics Symposium taking place November 13-16 in Dublin (Press release, Syros Pharmaceuticals, OCT 30, 2018, View Source [SID1234530428]). The presentation will include data on safety, pharmacokinetics and proof-of-mechanism. These data will be the first clinical data presented on a selective CDK7 inhibitor, marking a significant milestone in the development of selective CDK7 inhibitors for the treatment of cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In additional poster presentations, Syros will present new preclinical data on the mechanistic rationale for SY-1365 in combination with carboplatin in ovarian cancer; the first preclinical data on its oral CDK7 inhibitor program; and the discovery of drug targets and patient subsets from its analysis of the super-enhancer landscape in ovarian cancer.
The abstract for the oral presentation on SY-1365 will remain under embargo until the day of the presentation. The abstracts for the poster presentations are now available online on the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) conference website at View Source
Details on the oral presentation are as follows:
Presentation Title: Proof-of-Mechanism Based on Target Engagement and Modulation of Gene Expression Following Treatment with SY-1365, a First-in-Class Selective CDK7 Inhibitor in Phase 1 Patients with Advanced Cancer
Session Date & Time: Thursday, November 15, 14:30-15:45 GMT (9:30-10:45 a.m. ET)
Presentation Time: 15:30-15:45 GMT (10:30-10:45 a.m. ET)
Session Title: Plenary Session 6: Proffered Papers
Presenter: Dejan Juric, M.D., Massachusetts General Hospital
Abstract Number: 11
Location: Auditorium, The Convention Centre Dublin
Details on the poster presentations are as follows:
Presentation Title: SY-1365, a selective CDK7 inhibitor, enhances carboplatin activity in ovarian cancer cell lines and xenografts, and transcriptionally inhibits homologous recombination repair (HRR) genes
Date & Time: Tuesday, November 13, 12:00-19:00 GMT (7:00 a.m.-2:00 p.m. ET)
Session Title: Poster Session: DNA Repair Modulation
Presenter: Liv Johannessen, Ph.D., Syros
Abstract Number: 50
Location: PB-001, Exhibition Hall, The Convention Centre Dublin
Presentation Title: An oral and selective CDK7 inhibitor demonstrates substantial anti-tumor effect in breast and ovarian cancer models
Date & Time: Tuesday, November 13, from 12:00-19:00 GMT (7:00 a.m.-2:00 p.m. ET)
Session Title: Poster Session: Molecular Targeted Agents – PART 1
Presenter: Claudio Chuaqui, Ph.D., Syros
Abstract Number: 96
Location: PB-047, Exhibition Hall, The Convention Centre Dublin
Presentation Title: Super-enhancer landscapes of ovarian cancer reveal novel epigenomic subtypes and targets
Date & Time: Friday, November 16, from 10:00-14:00 GMT (5:00-9:00 a.m. ET)
Session Title: Poster Session: Molecular Targeted Agents – PART II
Presenter: Matthew Eaton, Ph.D., Syros
Abstract Number: 400
Location: PB-063, Exhibition Hall, The Convention Centre Dublin